Literature DB >> 34929590

Enhanced cross protection by hetero prime-boost vaccination with recombinant influenza viruses containing chimeric hemagglutinin-M2e epitopes.

Bo Ryoung Park1, Jeeva Subbiah1, Ki-Hye Kim1, Young-Man Kwon1, Judy Oh1, Min-Chul Kim2, Chong-Hyun Shin1, Baik Lin Seong3, Sang-Moo Kang4.   

Abstract

Annual repeat influenza vaccination raises concerns about protective efficacy against mismatched viruses. We investigated the impact of heterologous prime-boost vaccination on inducing cross protection by designing recombinant influenza viruses with chimeric hemagglutinin (HA) carrying M2 extracellular domains (M2e-HA). Heterologous prime-boost vaccination of C57BL/6 mice with M2e-HA chimeric virus more effectively induced M2e and HA stalk specific IgG antibodies correlating with cross protection than homologous prime-boost vaccination. Induction of M2e and HA stalk specific IgG antibodies was compromised in 1-year old mice, indicating significant aging effects on priming subdominant M2e and HA stalk IgG antibody responses. This study demonstrates that a heterologous prime-boost strategy with recombinant influenza virus expressing extra M2e epitopes provides more effective cross protection than homologous vaccination.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cross protection; Live attenuated virus; M2e; Recombinant influenza virus

Mesh：

Substances：

Year:  2021        PMID： 34929590      PMCID： PMC8903020          DOI： 10.1016/j.virol.2021.12.003

Source DB:  PubMed          Journal:  Virology        ISSN： 0042-6822            Impact factor:   3.616


  49 in total

1.  Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope.

Authors:  Ki-Hye Kim; Yu-Jin Jung; Youri Lee; Bo Ryoung Park; Judy Oh; Yu-Na Lee; Min-Chul Kim; Subbiah Jeeva; Sang-Moo Kang
Journal:  Virology       Date:  2020-08-22       Impact factor: 3.616

2.  A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.

Authors:  Raffael Nachbagauer; Jodi Feser; Abdollah Naficy; David I Bernstein; Jeffrey Guptill; Emmanuel B Walter; Franceso Berlanda-Scorza; Daniel Stadlbauer; Patrick C Wilson; Teresa Aydillo; Mohammad Amin Behzadi; Disha Bhavsar; Carly Bliss; Christina Capuano; Juan Manuel Carreño; Veronika Chromikova; Carine Claeys; Lynda Coughlan; Alec W Freyn; Christopher Gast; Andres Javier; Kaijun Jiang; Chiara Mariottini; Meagan McMahon; Monica McNeal; Alicia Solórzano; Shirin Strohmeier; Weina Sun; Marie Van der Wielen; Bruce L Innis; Adolfo García-Sastre; Peter Palese; Florian Krammer
Journal:  Nat Med       Date:  2020-12-07       Impact factor: 53.440

3.  Repeated influenza vaccination for preventing severe and fatal influenza infection in older adults: a multicentre case-control study.

Authors:  Itziar Casado; Ángela Domínguez; Diana Toledo; Judith Chamorro; Jenaro Astray; Mikel Egurrola; María Amelia Fernández-Sierra; Vicente Martín; María Morales-Suárez-Varela; Pere Godoy; Jesús Castilla
Journal:  CMAJ       Date:  2018-01-08       Impact factor: 8.262

4.  Diminished B-Cell Response After Repeat Influenza Vaccination.

Authors:  Mrinmoy Sanyal; Tyson H Holmes; Holden T Maecker; Randy A Albrecht; Cornelia L Dekker; Xiao-Song He; Harry B Greenberg
Journal:  J Infect Dis       Date:  2019-04-19       Impact factor: 5.226

5.  Influenza vaccination responses: Evaluating impact of repeat vaccination among health care workers.

Authors:  Vivian K Y Leung; Louise A Carolan; Leon J Worth; Susan A Harper; Heidi Peck; Danielle Tilmanis; Karen L Laurie; Monica A Slavin; Sheena G Sullivan
Journal:  Vaccine       Date:  2017-04-03       Impact factor: 3.641

6.  Mortality associated with influenza and respiratory syncytial virus in the United States.

Authors:  William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Nancy Cox; Larry J Anderson; Keiji Fukuda
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

7.  Protection against respiratory syncytial virus by inactivated influenza virus carrying a fusion protein neutralizing epitope in a chimeric hemagglutinin.

Authors:  Yu-Na Lee; Hye Suk Hwang; Min-Chul Kim; Young-Tae Lee; Yu-Jin Kim; F Eun-Hyung Lee; Sang-Moo Kang
Journal:  Nanomedicine       Date:  2015-12-02       Impact factor: 5.307

8.  Advances in measuring influenza burden of disease.

Authors:  Vernon J Lee; Zheng Jie Marc Ho; Ee Hui Goh; Harry Campbell; Cheryl Cohen; Vanessa Cozza; Julia Fitzner; Jorge Jara; Anand Krishnan; Joseph Bresee
Journal:  Influenza Other Respir Viruses       Date:  2018-01       Impact factor: 4.380

9.  Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans.

Authors:  Surender Khurana; Megan Hahn; Elizabeth M Coyle; Lisa R King; Tsai-Lien Lin; John Treanor; Andrea Sant; Hana Golding
Journal:  Nat Commun       Date:  2019-07-26       Impact factor: 14.919

10.  Recombinant Live Attenuated Influenza Virus Expressing Conserved G-Protein Domain in a Chimeric Hemagglutinin Molecule Induces G-Specific Antibodies and Confers Protection against Respiratory Syncytial Virus.

Authors:  Yu-Jin Jung; Yu-Na Lee; Ki-Hye Kim; Youri Lee; Subbiah Jeeva; Bo Ryoung Park; Sang-Moo Kang
Journal:  Vaccines (Basel)       Date:  2020-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.